Protagonist Therapeutics 미래 성장

Future 기준 확인 5/6

Protagonist Therapeutics은 연간 수입과 매출이 각각 38.5%와 21.1% 증가할 것으로 예상되고 EPS는 연간 37.9%만큼 증가할 것으로 예상됩니다.

주요 정보

38.5%

수익 성장률

37.93%

EPS 성장률

Biotechs 수익 성장	23.6%
매출 성장률	21.1%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	22 May 2025

최근 미래 성장 업데이트

Recent updates

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Mar 11

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up

Mar 11

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Jan 13

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Oct 16

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19

수익 및 매출 성장 예측

NasdaqGM:PTGX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	137	-76	N/A	-122	6
12/31/2026	189	27	N/A	74	9
12/31/2025	82	-112	N/A	-77	10
3/31/2025	208	56	335	337	N/A
12/31/2024	434	275	183	184	N/A
9/30/2024	324	171	229	230	N/A
6/30/2024	319	170	231	232	N/A
3/31/2024	315	162	-64	-63	N/A
12/31/2023	60	-79	-71	-70	N/A
9/30/2023	N/A	-140	-119	-119	N/A
6/30/2023	N/A	-138	-118	-117	N/A
3/31/2023	1	-140	-105	-105	N/A
12/31/2022	27	-127	-109	-108	N/A
9/30/2022	35	-130	-104	-103	N/A
6/30/2022	45	-133	-108	-107	N/A
3/31/2022	47	-122	-118	-117	N/A
12/31/2021	27	-126	-109	-108	N/A
9/30/2021	24	-108	-101	-100	N/A
6/30/2021	27	-81	-88	-88	N/A
3/31/2021	31	-70	-86	-85	N/A
12/31/2020	29	-66	-73	-72	N/A
9/30/2020	26	-65	-68	-68	N/A
6/30/2020	17	-73	-66	-66	N/A
3/31/2020	2	-83	-42	-41	N/A
12/31/2019	0	-77	-42	-42	N/A
9/30/2019	0	-74	-38	-37	N/A
6/30/2019	2	-66	-34	-32	N/A
3/31/2019	22	-45	-52	-51	N/A
12/31/2018	31	-39	N/A	-50	N/A
9/30/2018	40	-28	N/A	-54	N/A
6/30/2018	43	-24	N/A	-4	N/A
3/31/2018	31	-31	N/A	-1	N/A
12/31/2017	20	-37	N/A	4	N/A
9/30/2017	9	-45	N/A	8	N/A
6/30/2017	N/A	-48	N/A	-39	N/A
3/31/2017	N/A	-40	N/A	-35	N/A
12/31/2016	N/A	-38	N/A	-30	N/A
9/30/2016	N/A	-32	N/A	-25	N/A
6/30/2016	N/A	-28	N/A	-22	N/A
3/31/2016	N/A	-24	N/A	-17	N/A
12/31/2015	N/A	-15	N/A	-14	N/A

애널리스트 미래 성장 예측

수입 대 저축률: PTGX 의 연간 예상 수익 증가율( 38.5% )이 saving rate( 2.9% 보다 높습니다. ).

수익 vs 시장: PTGX 의 연간 수익( 38.5% ) US 시장( 14.4% 보다 빠르게 성장할 것으로 예상됩니다. 14.4% 연간).

고성장 수익: PTGX 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: PTGX 의 수익(연간 21.1% ) US 시장( 8.6% 보다 빠르게 성장할 것으로 예상됩니다. 8.6% 연간).

고성장 수익: PTGX 의 수익(연간 21.1% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: PTGX 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/06/02 14:48
장 마감 주가	2025/05/30 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Protagonist Therapeutics, Inc. 21 애널리스트 중 10 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Douglas Tsao	Barclays
Mayur Somaiya	BMO Capital Markets Equity Research
Etzer Darout	BMO Capital Markets Equity Research

Protagonist Therapeutics 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 7.1% to US$43.00

Forecast to breakeven in 2024

Consensus revenue estimates fall by 25%

Price target increased by 10% to US$42.50

Consensus revenue estimates increase by 35%

Price target decreased by 9.1% to US$35.83

Recent updates

Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide

Protagonist Therapeutics, Inc., Annual General Meeting, Jun 20, 2025

Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Shares Climb 44% But Its Business Is Yet to Catch Up

Protagonist Therapeutics, Inc. Announces New Icotrokinra (Jnj-2113) Data from the Comprehensive Phase 3 Clinical Program and the Planned Initiation of the First-Ever Head-To-Head Study in Plaque Psoriasis

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera

Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck

Protagonist Therapeutics, Inc. Announces Transition of Suneel Gupta from Chief Development Officer to Executive Vice President, Clinical Development

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting

Protagonist Therapeutics, Inc. Announces Positive Topline Results from Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113)

The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey

Protagonist Therapeutics, Inc. Announces Publication of Phase 1 Clinical Data on JNJ-2113 in the Journal

Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Advisor, Effective August 1, 2024

Protagonist Therapeutics, Inc. Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showowing Durable Hematocrit Control

Investor sentiment improves as stock rises 16%

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

CEO, President notifies of intention to sell stock

Executive VP & Chief Financial Officer recently sold US$378k worth of stock

Executive VP & Chief Financial Officer notifies of intention to sell stock

Price target increased by 7.1% to US$43.00

Forecast to breakeven in 2024

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Consensus revenue estimates fall by 25%

Price target increased by 10% to US$42.50

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

CEO, President notifies of intention to sell stock

Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

Protagonist Therapeutics, Inc. Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-To-Head Comparisons with Deucravacitinib

Consensus revenue estimates increase by 35%

Price target decreased by 9.1% to US$35.83

Consensus revenue estimates increase by 102%

Protagonist Therapeutics, Inc. Announces Achievement of $50 Million Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis

Protagonist Therapeutics, Inc. Announces Appointment of Daniel N. Swisher, Jr. to Its Board of Director

Chief Development Officer exercised options to buy US$282k worth of stock.

Consensus revenue estimates increase by 250%

New minor risk - Profitability

Consensus revenue estimates fall by 30%

Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director

Price target increased by 7.3% to US$39.00

Protagonist Therapeutics, Inc., Annual General Meeting, May 27, 2024

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Price target increased by 9.1% to US$37.83

Consensus revenue estimates increase by 100%

Protagonist Reports Positive Results from Phase 1 and Pre-Clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113

Consensus revenue estimates decrease by 17%, EPS upgraded

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.43 loss in 1Q 2022)

Consensus revenue estimates fall by 51%

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Full year 2022 earnings: EPS and revenues miss analyst expectations

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor

Insider exercised options to buy US$812k worth of stock.

Insufficient new directors

Third quarter 2022 earnings released: US$0.64 loss per share (vs US$0.70 loss in 3Q 2021)

Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer

Price target decreased to US$34.40

CEO, President exercised options to buy US$187k worth of stock.

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Protagonist Therapeutics, Inc. to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022

Consensus revenue estimates increase by 28%

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Price target decreased to US$48.29

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$52.00

Insufficient new directors

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis